Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Rabbit Polyclonals
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Rabbit Polyclonals

[0498-bs-3922R-20ul] ADCY5 Polyclonal Antibody solution, 20ul trial size
ADCY5 Polyclonal Antibody solution, 20ul trial size
270.00 € 270.0 EUR
[0451-AS13 2640] ACT | Actin (polyclonal)
ACT | Actin (polyclonal)
650.00 € 650.0 EUR
[0795-DF2936-200ul] ABHD5 Antibody to Primary Rabbit Polyclonal - 200ul
ABHD5 Antibody to Primary Rabbit Polyclonal - 200ul
565.00 € 565.0 EUR
[0795-DF12065-200ul] ABHD5 Antibody to Primary Rabbit - Polyclonal - 200ul
ABHD5 Antibody to Primary Rabbit - Polyclonal - 200ul
565.00 € 565.0 EUR
[0806-A8589-20] ABCG5 Rabbit pAb, 20uL
ABCG5 Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0806-A4328-20] ABCG1 Rabbit pAb, 20uL
ABCG1 Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0806-A9835-20] ABCB4 Rabbit pAb, 20uL
ABCB4 Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0806-A20496-20] ABCA8A Rabbit pAb, 20uL
ABCA8A Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0806-A18280-20] ABCA7 Rabbit pAb, 20uL
ABCA7 Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0806-A3191-20] ABCA6 Rabbit pAb, 20uL
ABCA6 Rabbit pAb, 20uL
190.00 € 190.0 EUR
[0356-A-4036-050] Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody - 50 µl
Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody - 50 µl
450.00 € 450.0 EUR
[0356-A-4022-100] Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody - 100ul
Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody - 100ul
632.00 € 632.0 EUR
[0356-A-4039-050] Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody - 50 µl
Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody - 50 µl
452.00 € 452.0 EUR
[0356-A-4708-050] Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody - 50 µl
Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody - 50 µl
410.00 € 410.0 EUR
[0384-BS90665-50ul] HSP20 polyclonal antibody 50ul
HSP20 polyclonal antibody 50ul
607.00 € 607.0 EUR
[0384-BS90665-100ul] HSP20 polyclonal antibody 100ul
HSP20 polyclonal antibody 100ul
797.00 € 797.0 EUR
[795-AF6403-200ul] HSL Antibody Primary Rabbit Polyclonal - 200ul
HSL Antibody Primary Rabbit Polyclonal - 200ul
565.00 € 565.0 EUR
[0498-BS-0239R] HIV gp41 Polyclonal Antibody 100ul
HIV gp41 Polyclonal Antibody 100ul
585.00 € 585.0 EUR
[0498-bs-15478R-A647] HHLA1 Polyclonal Antibody, ALEXA FLUOR® 647 Conjug.ated - 100ul
HHLA1 Polyclonal Antibody, ALEXA FLUOR® 647 Conjug.ated - 100ul
568.00 € 568.0 EUR
[0544-MBS534530-1ml] Guinea Pig anti-Human Insulin Polyclonal Antibody -1 mLanti-INS antibody :: Guinea Pig anti-Human Insulin Polyclonal Antibody
Guinea Pig anti-Human Insulin Polyclonal Antibody -1 mLanti-INS antibody :: Guinea Pig anti-Human Insulin Polyclonal Antibody
532.50 € 532.5 EUR
  • 1
  • 2
  • 3
  • 4
  • 5

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)